OTC Markets · Medical Devices · USD

Venus Concept Inc. (VERO) Stock Analysis

Venus Concept Inc. (VERO) is a Medical Devices stock listed on OTC Markets and quoted in US Dollar.

VERO

$0.31

+$0.01 (+2.64%)

Last trade April 6, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VERO with… →

VERO Key Statistics

As of Apr 6, 2026

Trading

Open: $0.27
Previous Close: $0.30
Day's Range: 0.27–0.27
52-Week Range: 0.25–12.93
Volume: 43
Beta: −0.06

Valuation

Market Cap: $578.19K
P/E Ratio: unprofitable
EPS (ttm): −45.26

Financials (FY)

Profit margin: −92.76%
1-Year Return: −86.82%

Dividend and dates

Avg Volume: 6.41M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VERO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	−78.99%
2025	−62.63%

As of April 6, 2026.

VERO Valuation vs Medical Devices Median

Median of 151 stocks

Metric	VERO	Medical Devices median	vs median
P/S ratio	0.01	2.98	0.0x the median
Profit margin	−92.76%	−1.69%	91.1 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Venus Concept Inc. (VERO) at $578.19K. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 292.

The most recent close on file for VERO is $0.31, dated April 6, 2026. That is +$0.01 (+2.64%) against the previous close. The 52-week range on file runs from $0.25 to $12.93. The latest close sits 25.91% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $58.88M. Profit margin runs at −92.76%. That is 91.1 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −45.26.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −86.82%. Beta against the wider market is reported at −0.06. Daily returns over the trailing 1 year annualize to a volatility of 528.63%.

Growth & Income

The record shows no dividend for VERO.

The record holds one complete calendar year, 2025, which returned −62.63%. 2026 is still running; the price is −78.99% year to date.

Peer Comparison

Venus Concept Inc. (VERO) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Venus Concept Inc.	VERO	$578.19K	—
Abbott Laboratories	ABT	$187.45B	35.1
Medtronic plc.	MDT	$120.46B	22.9
Stryker Corporation	SYK	$116.27B	31.9

The Medical Devices industry average P/E ratio is 26.8x. Venus Concept Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of April 6, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

MDT

Medtronic plc.

$120.46B

SYK

Stryker Corporation

$116.27B

BSX

Boston Scientific Corporation

$69.27B

Edwards Lifesciences Corporation

$51.82B

DXCM

DexCom, Inc.

$33.17B

View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Venus Concept Inc.

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, a portable and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF combined with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, flanks, back, and thighs in individuals with a body mass index BMI of 30 or less; Venus Glow, a Motorized dermabrasion device used to improve skin appearance; and NeoGraft, a hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.

Visit website →